Cositecan
- Generic Name
- Cositecan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N2O4Si
- CAS Number
- 203923-89-1
- Unique Ingredient Identifier
- 24R60NVC41
- Background
Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
- Indication
Investigated for use/treatment in brain cancer, lung cancer, and melanoma.
- Associated Conditions
- -
- Associated Therapies
- -
Karenitecin in Treating Patients With Recurrent Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00014521
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath